Analyst
Guggenheim Partners
Equibles does not estimate personal net worth.
Michael Schmidt is recorded as Analyst at Guggenheim Partners. Michael Schmidt has spoken on 4 earnings calls across 3 companies, most recently for Genmab A/S on August 6, 2026. Those appearances were for Genmab A/S (GMAB), BeOne Medicines Ltd. (ONC) and BEONE MEDICINES LTD.. The companies whose calls Michael Schmidt spoke on are classified in the Healthcare sector.
“I had one on EPCOR DLBCL2 and I'm just trying to wrap my head around the timing of the interim analysis in the fourth quarter this year. Based on our work, we think this should have already occurred at some point last year.”
“Maybe just in terms of the enrollment of the study, Tahi, could you just comment on how enrollment has been relative to your expectations when starting the trial?”
“I had a commercial question around the BTK inhibitor market and Brookingsa.”
“I had a commercial question around the BTK inhibitor market and Brukinsa.”
Guggenheim Partners
Analyst
Transcript header (unverified)
GMAB
Biotechnology · Healthcare
BEONE MEDICINES LTD.
Biotechnology · Healthcare
Q4 and Full Year 2025 Results
BEONE MEDICINES LTD.
